Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy

HER2 (ERBB2) amplification is a driving oncogenic event in breast cancer. Clinical trials have consistently shown the benefit of HER2 inhibitors (HER2i) in treating patients with both local and advanced HER2+ breast cancer. Despite this benefit, their efficacy as single agents is limited, unlike the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Floros, Konstantinos V., Lochmann, Timothy L., Hu, Bin, Monterrubio, Carles, Hughes, Mark T., Wells, Jason D., Morales, Cristina Bernadó, Ghotra, Maninderjit S., Costa, Carlotta, Souers, Andrew J., Boikos, Sosipatros A., Leverson, Joel D., Tan, Ming, Serra, Violeta, Koblinski, Jennifer E., Arribas, Joaquin, Prat, Aleix, Paré, Laia, Miller, Todd W., Dozmorov, Mikhail G., Harada, Hisashi, Windle, Brad E., Scaltriti, Maurizio, Faber, Anthony C.
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2018
Assuntos:
PNAS Plus
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5856537/
https://ncbi.nlm.nih.gov/pubmed/29476008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1717820115
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados